The booster shot – called mRNA-1273.211 – offered better and longer-lasting protection compared to the original SpikeVax shot against all SARS-CoV-2 variants, including the prevailing Omicron ...

Moderna's new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company's original Spikevax shot in a head-to-head clinical trial.

“Moderna has repeatedly touted the speed at which it produced its original Spikevax vaccine and was later able to modify it to address new viral strains,” GSK said. “But Moderna has ...

In a related JAMA Viewpoint, the authors noted that COVID-19 peaked in 2020 and 2021 as the third highest cause of mortality ...

[emphasis in original] Yee cited by name Moderna (NASDAQ ... and higher-than-expected sales of its COVID-19 vaccine Spikevax® ...

“Moderna has repeatedly touted the speed at which it produced its original Spikevax vaccine and was later able to modify it to address new viral strains,” GSK said. “But Moderna has consistently ...

The Massachusetts-based company said that third-quarter revenue from its Spikevax shot came in at $1.8 billion, with $1.2 billion of the sales coming in the United States. The overall figure ...

According to Reuters, the company earned $6.7 billion in revenue from Spikevax in 2023. Moderna has stated in the past that it is “not aware of any significant intellectual property impediments ...

Shares up nearly 5% to $54.22 in early trading Spikevax COVID vaccine sales reached $1.8 billion, beating expectations Moderna expects lower COVID vaccine sales this year compared to 2023 $10 ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

The lawsuit said, opens new tab Moderna uses Northwestern-developed lipid nanoparticle (LNP) technology without a license in Spikevax shots to transport fragile messenger RNA into the human body.